AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GRAL · NASDAQ · Medical - Diagnostics & Research

GRAIL

Developer of Galleri and targeted methylation tools for cancer detection.

$80.00

After-hours close−0.01 (−0.01%)

At close$80.01(−3.02%)

Something off on this page? Send us feedback.

Profile

GRAIL, Inc.GRALHealth Care

Sells Galleri, a physician-ordered blood test for multi-cancer early detection, and provides methylation-based development services to biopharmaceutical partners. Screening drives most revenue; the U.S.-centered business relies on certified laboratory operations, clinical evidence, FDA review, and broader reimbursement.

Markets Galleri, a physician-ordered blood test that screens for a signal shared by multiple cancers and predicts its likely origin. Screening-test sales produce most revenue, while a targeted methylation platform supports research-use classifiers and precision-oncology development services for biopharmaceutical partners. Tests are processed at a CAP-accredited, CLIA-certified laboratory in Durham, North Carolina.

Commercial activity remains centered in the United States, with limited partner-led access in other markets. Execution combines population-scale clinical studies, sequencing, machine-learning classifiers, laboratory automation, and physician-support workflows. Galleri is offered as a laboratory-developed test and is designed to complement recommended single-cancer screening; it is not FDA-approved, and its premarket approval application remains under review. Illumina is the sole supplier of sequencers and certain reagents, and related oncology revenue carries a continuing royalty obligation.

Company facts

CEOJoshua J. Ofman

ListedJun 12, 2024

ExchangeNASDAQ

HeadquartersMenlo Park, CA

CountryUnited States

Employees910

CIK0001699031

ISINUS3847471014

Key statistics

Market cap$3.43B

EPS (ttm)−$9.75

P/E (ttm)−8.21

ROE-15.9%

P/B1.36

P/S20.77

Dividend yield—

Beta2.72vs XLV 0.63

Year to date −10.0% · Average volume (30d) 690.5K

Analysts

Price target, next 12 months$62.50−21.9%Median of 7 analysts · vs the Aug 28 close

ConsensusBuy4 of 7 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $80.00

High$70.00−12.5%

Median$62.50−21.9%

Low$56.00−30.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Jul 15, 2026	Mizuho Securities	Target		$58	$65
Jun 5, 2026	Goldman Sachs	Target			$60
May 6, 2026	Piper Sandler	Reiterate	Neutral	$54	$56
May 6, 2026	Robert W. Baird	Target		$82	$70
Apr 10, 2026	Mizuho Securities	Target			$58

Earnings

EPS

Estimate−$2.60

ReportedDue Nov 11, 2026

Revenue

Estimate$44.3M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$2.66	−$2.56	+3.8%	$42.4M	$44.7M	+5.4%	−14.53%
May 5, 2026Q1 FY26	−$2.76	−$2.29	+17.1%	$39.2M	$40.8M	+4.2%	+15.35%
Feb 19, 2026Q4 FY25	−$3.33	−$2.44	+26.7%	$43.6M	$43.6M	0.0%	−50.55%
Nov 12, 2025Q3 FY25	−$3.36	−$2.46	+26.8%	$34.6M	$36.2M	+4.6%	−1.85%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$31.8M	$35.5M	$36.2M	$43.6M	$40.8M	$44.7M
Gross profit	−$19.9M	−$17.8M	−$13.7M	−$11.1M	$19.5M	−$12.6M
Operating income	−$153.6M	−$158.9M	−$125.3M	−$124.4M	−$135.8M	−$173.8M
Net income	−$106.2M	−$114.0M	−$89.0M	−$99.2M	−$93.2M	−$110.2M
Diluted EPS	−$3.10	−$3.18	−$2.46	−$2.44	−$2.29	−$2.56
Gross margin	-62.6%	-50.0%	-37.9%	-25.5%	47.9%	-28.1%
Operating margin	-482.5%	-446.9%	-346.2%	-285.4%	-332.9%	-388.9%

Fiscal years (4-quarter sums)FY23 $93.1M · FY24 $125.6M · FY25 $147.2M

Revenue by geography · Q2 FY26

United States$41.4M · 96%

Non-US$1.8M · 4%

Balance sheet, Jun 30, 2026Cash & short-term investments $861.6M · Total debt $91.3M · Total assets $2.84B · Shareholders' equity $2.54B

Dividends

No dividends on record.

Ownership

Institutions 96.23%41.30M sharesInsiders 3.54%1.52M sharesOther 0.23%97.6K shares

Shares outstanding 42.92M · Float 39.29M · 91.6% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Farallon Capital Management LLC	4.16M	9.70%	13F	Aug 14, 2026
Baker Bros. Advisors LP	4.03M	9.39%	13F	Aug 14, 2026
BlackRock, Inc.	3.58M	8.33%	13F	Aug 7, 2026
Illumina, Inc. · 10 percent owner	3.50M	8.16%	Form 4	Nov 18, 2025
Ding Chun R · 10 percent owner	3.31M	7.70%	Form 4	Jul 3, 2025

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jun 4, 2026	Andrew John Partridge	officer: Chief Growth Officer	−1,491	$61.08
Apr 8, 2026	Joshua J. Ofman	director, officer: President	−61,665	$49.92
Apr 8, 2026	Robert P. Ragusa	director, officer: Chief Executive Officer	−123,502	$49.92
Apr 8, 2026	Aaron Freidin	officer: Chief Financial Officer	−45,806	$49.92
Mar 9, 2026	Robert P. Ragusa	director, officer: Chief Executive Officer	−7,461	$47.89